Q-omics provides the consensus-scored PAXIP1-DT profile across patient tissues and cancer cell-line models. PAXIP1-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, PAXIP1-DT is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PAXIP1-DT RNA expression shows 19,530 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight OV, COAD, and LSCC as cancer lineages where PAXIP1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAXIP1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAXIP1-DT survival associations across molecular data types. PAXIP1-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAXIP1-DT RNA expression–survival associations across cancer types. High PAXIP1-DT expression shows unfavorable associations in UVM and KICH, but favorable associations in OV, STAD, BRCA and HNSC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for PAXIP1-DT RNA expression.
This table summarizes PAXIP1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PAXIP1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAXIP1-DT shows lower tumor expression in THCA and KIRC and higher tumor expression in COAD, BLCA, LIHC and HNSC. The COAD box plot shows higher PAXIP1-DT RNA expression in tumor versus normal tissue (log2 FC = +0.882, t-test p < 0.001).
This table shows molecular features associated with PAXIP1-DT in patient tissues and cancer cell lines. In patient samples, PAXIP1-DT shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
